Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)

Group 1 - Aurinia Pharmaceuticals Inc.'s Lupkynis sales appeared to have peaked in early to mid-2024, with stock prices falling below $5 [1] - Q1 2024 earnings report indicated a resumption of sales growth for Lupkynis in May [1]